Sílvia Narejos Pérez

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

R. Dagan, M. Haranaka, A. Pedley, 2021, Vaccine.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Telemedicine in the face of the COVID-19 pandemic

J. Vidal-Alaball, F. López Seguí, Danielle Morrison, 2020, Atención Primaria.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

Chong-Jen Yu, Wen-Yuan Lin, M. Peeters, 2013, BMC Infectious Diseases.

Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study

J. Pirçon, Rajul Patel, I. Leroux-Roels, 2023, Open forum infectious diseases.

Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.

E. Kerwin, H. Watz, F. Maltais, 2022, The Lancet. Respiratory medicine.